ConjuLink™ Phase II Metabolic Stability Research Kit

CAT#: ITS-0326-WB6
Product Type: Assay Kit
Species: General (All species)
Target: Phase II drug-metabolizing enzymes
Brand: ConjuLink™
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Evaluates Phase II metabolic stability of drug candidates through enzymatic conjugation reactions in vitro.
Brand
ConjuLink™
Development Stage
ADME
ADME Research Domain
Metabolism
Description
ConjuLink™ Phase II Metabolic Stability Research Kit provides a robust in vitro platform for assessing the conjugation-mediated metabolic stability of drug candidates. The system incorporates optimized Phase II metabolic enzymes and cofactors to simulate glucuronidation and other conjugation pathways. This assay enables rapid characterization of metabolic clearance, conjugate formation, and compound susceptibility to Phase II metabolism during early drug development.
Features
Incorporates optimized recombinant conjugation enzymes and essential cofactors, enabling reliable assessment of Phase II metabolic turnover and conjugate formation in vitro.
Designed for compatibility with diverse small molecules, supporting evaluation of metabolic stability across a wide range of pharmaceutical and bioactive compounds.
Streamlined microplate-based workflow facilitates reproducible metabolic profiling and efficient throughput suitable for drug discovery and pharmacokinetic research programs.
Carefully optimized reaction conditions enhance enzymatic activity and improve detection of conjugated metabolites for accurate metabolic stability evaluation.
Process Relevance
Evaluates susceptibility of compounds to Phase II metabolic conjugation, supporting prediction of metabolic clearance and drug disposition.
Application Stage
Early drug discovery, ADME profiling, metabolic stability studies, and lead optimization.
Applications
Assessment of glucuronidation and conjugation reactions, metabolic stability screening of drug candidates, metabolite identification studies, ADME profiling, and pharmacokinetic characterization using recombinant enzyme systems.
Qualified With
Internal performance validation using reference standards under defined assay conditions.
Target
Phase II drug-metabolizing enzymes
Sample Type
Tissue homogenates, cell lysates, and other biological fluids.
Assay Measures
Quantitative
Research Areas
Drug metabolism & pharmacokinetics (ADME), pharmaceutical sciences, toxicology, medicinal chemistry, pharmacology, xenobiotic metabolism, etc.
Size
50 tests
Data Output Type
Quantitative metabolite formation or metabolic stability measurement using LC-MS or enzymatic activity detection.
Species
General (All species)
Assay Measures
Quantitative
Storage
Upon receipt, store the kit in accordance with the storage conditions specified in the product manual.
Storage Comment
Avoid repeated freeze-thaw cycles. During use, minimize the time components are exposed to room temperature and return them promptly to -20°C; storage after handling. Do not store at elevated temperatures for extended periods.
Expiry Date
12 months under recommended storage conditions to ensure optimal performance.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Shipped on ice under temperature-controlled conditions.
Background
Phase II metabolism plays a critical role in detoxification and clearance of xenobiotics. Conjugation enzymes such as UDP-glucuronosyltransferases catalyze the attachment of hydrophilic groups to small molecules, increasing their solubility and facilitating elimination. Evaluating Phase II metabolic stability is therefore essential for predicting drug clearance, potential metabolite formation, and pharmacokinetic behavior during drug development.
Pathways
Phase II metabolic enzymes function within the xenobiotic biotransformation network, typically following oxidative modifications generated by Phase I cytochrome P450 enzymes. Conjugation reactions such as glucuronidation, sulfation, and acetylation increase compound polarity, enabling efficient transport and excretion via hepatic and renal pathways.
For Research Use Only | Not For Clinical Use
Online Inquiry